Adia Nutrition, Inc.

Adia Nutrition, Inc. is a U.S.-based healthcare and nutrition company organized around operating subsidiaries that provide medical procedures, biologic products, and related ancillary services. Its business is centered in the United States and is structured through entities including Adia Med, Adia Labs, and Biolete, LLC.

−51,7 %

27,4 %

−56,5 %

+10 879,7 %

1.11

0.94

— Adia Nutrition, Inc.
%
Medical procedures60% Clinical procedures and related patient services performed through the Adia Med business.
Biologic products35% Sales of biologic products recognized net of discounts and refunds.
Ancillary products and supplements3% Smaller product sales tied to the company’s healthcare and nutrition offering.
Shipping and delivery2% Fulfillment and delivery charges associated with product sales.

The company serves U.S. customers that purchase medical procedures directly through its healthcare operations and...

  • Medical procedure patientsprimary

    Individuals purchasing procedures from Adia Med for direct clinical services.

  • Biologic product customersprimary

    Customers buying biologic products sold through the company’s product channel.

  • Supplement and ancillary product buyerssecondary

    Customers purchasing smaller nutrition or support products alongside core services.

  • Shipping and fulfillment customersemerging

    Customers whose orders include delivery charges and logistics services.

The company reports that it has no operations or sources of revenue outside the United States, so its business is...

  • •All revenue is generated in the United States
  • •No disclosed operations outside the U.S.
  • •Domestic concentration ties results to U.S. healthcare demand
  • •U.S. regulation and reimbursement environment matter materially

Adia Nutrition’s stated direction is to grow revenue by expanding its medical and biologic offerings while using...

01
Expand revenue from core healthcare and biologic offeringsshort-term

The business depends on increasing sales volume across procedures and product channels.

02
Secure funding for working capital and growthshort-term

The company needs external capital to support operations, receivables, and expansion.

The company faces going-concern and financing risk because it depends on continued access to capital and higher revenue...

critical

Going-concern uncertainty

The company states it needs higher revenue and third-party capital to continue as a going concern.

Scope
Operations, liquidity, and continuity of the business
Materiality
high
high

Dependence on external financing

Growth and working capital rely on a line of credit and capital raises.

Scope
Bridge capital, receivables financing, operating cash needs
Materiality
high
medium

Related-party dependence

The company leases office space from and receives working capital support from an entity controlled by the CEO and director.

Scope
Governance, financing flexibility, and related-party terms
Materiality
medium
medium

U.S. market concentration

All revenue is generated in the United States, increasing exposure to domestic demand and regulation.

Scope
Healthcare regulation, reimbursement, consumer demand
Materiality
medium
Revenue recognition under ASC 606
Can affect timing and comparability of quarterly revenue
Use of estimates
Can materially affect reported results if assumptions change
Long-lived asset impairment
May create non-cash charges if asset values are not recoverable
Related-party transactions
Affects expense classification, disclosure, and financing terms

ADMA BIOLOGICS, INC.

ADMA · Biological Products, (No Diagnostic Substances)

DYADIC INTERNATIONAL INC

DYAI · Biological Products, (No Diagnostic Substances)

Archer-Daniels-Midland Co

ADM · Fats & Oils

Pluri Inc.

PLUR · Biological Products, (No Diagnostic Substances)

Bodhi Tree Biotechnology Inc

BDTB · Services-Management Consulting Services

MEDIFAST INC

MED · Miscellaneous Food Preparations & Kindred Products

: 11/08/2026